<DOC>
	<DOCNO>NCT00622323</DOCNO>
	<brief_summary>This prospective , non-interventional , post marketing surveillance study determine proportion patient experience adverse event list experience adverse event , serious non-serious , would occur among Filipino patient type 2 diabetes mellitus treat exenatide take metformin , sulfonylurea combination metformin sulfonylurea achieve adequate glycemic control .</brief_summary>
	<brief_title>Post Marketing Surveillance Study Byetta â„¢ ( Exenatide ) Use Among Filipino Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>male female outpatient least 18 year age provide write consent release data inform study diagnose type 2 diabetes mellitus take metformin , sulfonylurea reliable , agree keep appointment clinic visit , complete test procedure may require attend physician course routine clinical care treat exenatide accord approve Product Insert , prescribe investigator routine care patient simultaneously participate different study include treatment intervention and/or investigational drug . currently take insulin . pregnant intention become pregnant within duration study . investigator immediate family . Immediate family define investigator 's spouse , parent , natural legally adopt child ( include stepchild living investigator 's household ) , grandparent , grandchild . Employees investigator also eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>metformin</keyword>
	<keyword>sulfonylurea</keyword>
	<keyword>Byetta</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>